Lack of association between interleukin-6 promoter polymorphism at position -174 and Henoch-Schönlein purpura

OBJECTIVE:To assess whether poly-morphism of the interleukin (IL)-6 gene at the position -174 was implicated in the incidence of Henoch-SchA¶nlein pur-pura (HSP). A further objective was to determine if any relationship existed with severe systemic complications of HSP, in particular with severe renal and gastrointestinal involvement. METHODS:Unselected patients from Northwest Spain with primary cutaneous vasculitis classified as HSP according to proposed criteria were studied. All patients included in the present study were required to have had at least 2 year's follow-up. Patients and controls were genotyped for a single biallelic (G/C) nucleotide polymorphism in the promoter region at the position -174 of the IL-6 gene by a polymerase reaction chain-restriction fragment length polymorphism (PCR-RFLP) method.RESULTS:Forty-six Caucasian HSP pa-tients and 124 healthy matched controls were studied. No allele or genotype differences between the whole group of HSP and controls were observed. This was also the case when HSP patients were stratified by the presence of gastrointestinal complications, nephritis, and permanent renal involvement (renal sequelae).CONCLUSION:The polymorphism in IL-6 gene promoter (-174 G/C) does not appear to be a genetic risk factor for HSP in Northwest Spain.

[1]  L. Cimino,et al.  Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. , 2005, The Journal of rheumatology.

[2]  W. Ollier,et al.  Inducible nitric oxide synthase polymorphism is associated with susceptibility to Henoch-Schönlein purpura in northwestern Spain. , 2005, The Journal of rheumatology.

[3]  A. Pawlik,et al.  IL‐6 promoter polymorphism in patients with rheumatoid arthritis , 2005, Scandinavian journal of rheumatology.

[4]  M. González-Gay,et al.  Implications of upper respiratory tract infections and drugs in the clinical spectrum of Henoch-Schönlein purpura in children. , 2004, Clinical and experimental rheumatology.

[5]  W. Ollier,et al.  Interleukin 1beta gene polymorphism association with severe renal manifestations and renal sequelae in Henoch-Schönlein purpura. , 2004, The Journal of rheumatology.

[6]  W. Thomson,et al.  Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis. , 2002, The Journal of rheumatology.

[7]  W. Thomson,et al.  Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schönlein purpura. , 2002, The Journal of rheumatology.

[8]  W. Thomson,et al.  HLA-B35 association with nephritis in Henoch-Schönlein purpura. , 2002, The Journal of rheumatology.

[9]  W. Thomson,et al.  IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. , 2002, Clinical and experimental rheumatology.

[10]  M. González-Gay,et al.  Epidemiology of the vasculitides. , 2001, Rheumatic diseases clinics of North America.

[11]  W. Thomson,et al.  HLA-DRB1*01 association with Henoch-Schönlein purpura in patients from northwest Spain. , 2001, The Journal of rheumatology.

[12]  A. Balsa,et al.  IL-6 promoter polymorphisms in rheumatoid arthritis , 2000, Genes and Immunity.

[13]  A. Bakkaloğlu,et al.  The role of cytokines in Henoch Schonlein purpura. , 1997, Scandinavian journal of rheumatology.

[14]  G. Hunder,et al.  Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. , 1992, The Journal of rheumatology.